12:00 AM
 | 
Apr 06, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Avastin bevacizumab regulatory update

FDA's Oncologic Drugs Advisory Committee voted 10-0 that the response seen with Avastin bevacizumab from Roche's Genentech Inc. unit in patients with previously treated glioblastoma multiforme (GBM) is of sufficient magnitude to...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >